6665-71-0

Usage

InChI:InChI=1/C16H12O4/c1-19-13-7-3-2-5-10(13)15-9-12(18)16-11(17)6-4-8-14(16)20-15/h2-9,17H,1H3

Upstream product

• 6674-39-1 5,2′-dihydroxyflavone 
• 77-78-1 dimethyl sulfate 
• 2040-04-2 2,6-dimethoxyacetophenone 
• 78646-28-3 2′-hydroxy-6′-methoxymethoxyacetophenone 
• 135-02-4 ortho-anisaldehyde 
• 1443430-26-9 5-(benzyloxy)-2-(2-methoxyphenyl)-4H-chromen-4-one 
• 1443430-24-7 (E)-1-(2-(benzyloxy)-6-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one 
• 4047-24-9 1-[2-(benzyloxy)-6-hydroxyphenyl]ethanone 
• 699-83-2 2,6-dihydroxylacetophenone 
• 856814-53-4 1-(2-benzyloxy-phenyl)-3-(2,6-dimethoxy-phenyl)-propane-1,3-dione 
• 856814-81-8 1-(2-hydroxy-6-methoxy-phenyl)-3-(2-methoxy-phenyl)-propane-1,3-dione 
• 55142-16-0 methyl 2-(benzyloxy)benzoate 
• 74670-11-4 2',6'-Dimethoxyflavone 

Relevant academic research and scientific papers

Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists

Farnesoid X receptor (FXR), a nuclear receptor mainly distributed in liver and intestine, has been regarded as a potential target for the treatment of various metabolic diseases, cancer and infectious diseases related to liver. Starting from two previously identified chalcone-based FXR antagonists, we tried to increase the activity through the design and synthesis of a library containing chalcones, flavones and chromenes, based on substitution manipulation and conformation (ring closure) restriction strategy. Many chalcones and four chromenes were identified as microM potent FXR antagonists, among which chromene 11c significantly decreased the plasma and hepatic triglyceride level in KKay mice.

Development of flavonoid-based inverse agonists of the key signaling receptor US28 of human cytomegalovirus

A series of 31 chalcone- and flavonoid-based derivatives were synthesized in good overall yields and screened for their inverse agonist activity on the US28 receptor of human cytomegalovirus (HCMV). With one exception (e.g., 2-(5-bromo-2-methoxyphenyl)-3-hydroxy-4H-chromen-4-one), halogen-substituted flavonoids were typically more potent inverse agonists than their related hydro derivatives. While toxicity could be used to partially explain the inverse agonist activity of some members of the series, 5-(benzyloxy)-2-(5-bromo-2- methoxyphenyl)-4H-chromen-4-one (11b) acted on the US28 receptor as a nontoxic, inverse agonist. The full inverse agonism (efficacy, -89%) and potency (EC 50 = 3.5 μM) observed with flavonoid 11b is especially important as it provides both a new tool to study US28 signaling and a potential platform for the future development of HCMV-targeting drugs.